The picture that emerges from General Motors's disclosures about events that led to the recent recalls of 1.6 million vehicles is of a company still burdened by bureaucratic complexity, and unable to respond decisively.
Ranbaxy Laboratories, the India-based generic-drug maker beset by manufacturing-quality problems, has issued another recall of generic versions of the cholesterol drug Lipitor in the U.S. because of a potential dose mix-up.
Mexico took unprecedented strides to rein in the country's telecommunications and television operators, imposing a rash of measures on the phone companies of billionaire Carlos Slim and on the country's top broadcaster Grupo Televisa in a bid to improve competition in their markets.
General Motors has apologized profusely in recent days for an ignition-switch defect that existed for nine years and has been tied to at least 13 deaths in U.S. But apologies might be all many of the injured get.